[The efficacy of subcutaneous sumatriptan for the treatment of migraine attack].
Adam Stępień
Abstract
Adam Stępień
Abstract
Sumatriptan is a novel drug for the treatment of acute migraine attacks. The aim of this study was to assess the efficacy of a 6 mg s.c. Sumatriptan in the early acute treatment of migraine. Patients were recruited with a current history of migraine with and without aura. 58 patients treated 1 migraine attacks at home using an autoinjector with a dose 6 mg of sumatriptan. Patient assessed headache severity and other migraine symptoms 1 and 4 h after treatment. 55% patients reported headache relief after 1 h and 77% patients after 4 h. Adverse events were reported by 11% of patients. In conclusion, sumatriptan were effective and well tolerated in the acute treatment of migraine.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Sumatriptan is a novel drug for the treatment of acute migraine attacks. The aim of this study was to assess the efficacy of a 6 mg s.c. Sumatriptan in the early acute treatment of migraine. Patients were recruited with a current history of migraine with and without aura. 58 patients treated 1 migraine attacks at home using an autoinjector with a dose 6 mg of sumatriptan. Patient assessed headache severity and other migraine symptoms 1 and 4 h after treatment. 55% patients reported headache relief after 1 h and 77% patients after 4 h. Adverse events were reported by 11% of patients. In conclusion, sumatriptan were effective and well tolerated in the acute treatment of migraine.
Key concepts: Sumatriptan, Migraine, Medicine, Aura, Anesthesia, Adverse effect, Acute migraine, Migraine treatment